Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (161-170 of 464) with videos related to

Pageof 47
Sort By:
Alimentary Pharmacology & Therapeutics|October 29, 2020
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healingSushrut Jangi, Hyuk Yoon, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|October 14, 2020
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical PracticeNiels Vande Casteele, Brian G Feagan, Douglas C Wolf, et al.
The Lancet. Gastroenterology & Hepatology|October 22, 2018
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 scoreVipul Jairath, Jenny Jeyarajah, Guangyong Zou, et al.
The American Journal of Gastroenterology|January 8, 2014
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ RegistryGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
Inflammatory Bowel Diseases|January 29, 2005
A review of activity indices and end points for clinical trials in children with Crohn's diseaseAnne M Griffiths, Anthony R Otley, Jeffrey Hyams, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 21, 2020
Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACTJurij Hanzel, Christopher Ma, Guangyong Zou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2013
Treat to target: a proposed new paradigm for the management of Crohn's diseaseGuillaume Bouguen, Barrett G Levesque, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2021
Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative ColitisSushrut Jangi, Ariela K Holmer, Parambir S Dulai, et al.
Digestive Diseases and Sciences|September 25, 2004
High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot studyWilliam S Mow, Carol J Landers, A Hillary Steinhart, et al.
Inflammatory Bowel Diseases|April 7, 2015
Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysisMahmoud H Mosli, John K MacDonald, Stephen J Bickston, et al.
Pageof 47

Showing results (161-170 of 464) with videos related to

Sort By:
Pageof 47
Alimentary Pharmacology & Therapeutics|October 29, 2020
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healingSushrut Jangi, Hyuk Yoon, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|October 14, 2020
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical PracticeNiels Vande Casteele, Brian G Feagan, Douglas C Wolf, et al.
The Lancet. Gastroenterology & Hepatology|October 22, 2018
A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 scoreVipul Jairath, Jenny Jeyarajah, Guangyong Zou, et al.
The American Journal of Gastroenterology|January 8, 2014
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ RegistryGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
Inflammatory Bowel Diseases|January 29, 2005
A review of activity indices and end points for clinical trials in children with Crohn's diseaseAnne M Griffiths, Anthony R Otley, Jeffrey Hyams, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 21, 2020
Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACTJurij Hanzel, Christopher Ma, Guangyong Zou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2013
Treat to target: a proposed new paradigm for the management of Crohn's diseaseGuillaume Bouguen, Barrett G Levesque, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2021
Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative ColitisSushrut Jangi, Ariela K Holmer, Parambir S Dulai, et al.
Digestive Diseases and Sciences|September 25, 2004
High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot studyWilliam S Mow, Carol J Landers, A Hillary Steinhart, et al.
Inflammatory Bowel Diseases|April 7, 2015
Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysisMahmoud H Mosli, John K MacDonald, Stephen J Bickston, et al.
Pageof 47